THERAVANCE RELEASES RESULTS FROM STUDY OF SKIN INFECTION DRUG

Theravance has announced results from the ATLAS I and ATLAS II trials assessing the safety and efficacy of telavancin, a rapidly bactericidal injectable antibiotic, for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria.

ATLAS I and II were two large, multicenter, multinational, double-blind, randomized Phase III studies that enrolled and treated 1,867 patients, 719 of whom were infected with methicillin-resistant Staphylococcus aureus. In each study, telavancin achieved its primary endpoint of non-inferiority. In both clinical populations, the drug achieved a numerically better clinical cure rate and a better microbiological eradication rate than vancomycin in infections caused by Gram-positive bacteria.

The safety profile of telavancin was consistent with that observed in prior clinical studies. The most common adverse events reported in patients receiving telavancin were mild to moderate taste disturbance and nausea. In addition, consistent with previous studies, small percentages of telavancin-treated patients experienced renal adverse events.